SXTC vs. ATNF, ADTX, DMK, BLPH, EVFM, AMPE, NBY, NEPT, OBSV, and EVLO
Should you be buying China SXT Pharmaceuticals stock or one of its competitors? The main competitors of China SXT Pharmaceuticals include 180 Life Sciences (ATNF), Aditxt (ADTX), DMK Pharmaceuticals (DMK), Bellerophon Therapeutics (BLPH), Evofem Biosciences (EVFM), Ampio Pharmaceuticals (AMPE), NovaBay Pharmaceuticals (NBY), Neptune Wellness Solutions (NEPT), ObsEva (OBSV), and Evelo Biosciences (EVLO). These companies are all part of the "pharmaceutical preparations" industry.
180 Life Sciences (NASDAQ:ATNF) and China SXT Pharmaceuticals (NASDAQ:SXTC) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their community ranking, profitability, media sentiment, analyst recommendations, institutional ownership, risk, earnings, valuation and dividends.
China SXT Pharmaceuticals has higher revenue and earnings than 180 Life Sciences.
180 Life Sciences has a beta of 0.47, meaning that its stock price is 53% less volatile than the S&P 500. Comparatively, China SXT Pharmaceuticals has a beta of 1.02, meaning that its stock price is 2% more volatile than the S&P 500.
China SXT Pharmaceuticals received 80 more outperform votes than 180 Life Sciences when rated by MarketBeat users. However, 66.67% of users gave 180 Life Sciences an outperform vote while only 61.65% of users gave China SXT Pharmaceuticals an outperform vote.
4.1% of 180 Life Sciences shares are owned by institutional investors. Comparatively, 5.0% of China SXT Pharmaceuticals shares are owned by institutional investors. 4.1% of 180 Life Sciences shares are owned by insiders. Comparatively, 4.0% of China SXT Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
In the previous week, 180 Life Sciences had 1 more articles in the media than China SXT Pharmaceuticals. MarketBeat recorded 3 mentions for 180 Life Sciences and 2 mentions for China SXT Pharmaceuticals. 180 Life Sciences' average media sentiment score of 1.43 beat China SXT Pharmaceuticals' score of 0.44 indicating that China SXT Pharmaceuticals is being referred to more favorably in the news media.
180 Life Sciences' return on equity of 0.00% beat China SXT Pharmaceuticals' return on equity.
Summary
China SXT Pharmaceuticals beats 180 Life Sciences on 8 of the 11 factors compared between the two stocks.
Get China SXT Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for SXTC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SXTC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
China SXT Pharmaceuticals Competitors List
Related Companies and Tools